
Vitamin B12 (Cobalamin) is the largest B vitamin and was the last one to
be isolated in 1948 by Dr E. Lester Smith in the UK from liver. It is a red
crystalline substance. It had been known as early as 1926, that something
in raw liver was a treatment for anaemia. There are various forms of the B12
(so called due to the presence of cobalt) molecule, some of these are; methyl-,
cyano, adnosyl- and hydroxocobalamin (B12b). There are also nitrit (B12c),
sulphito and aquacobalamins. The human body can normally convert from one
to the other. The human body typically contains 5000-10000 mg of B12 distributed
about equally between the liver, kidneys and nervous system.
Indeed the liver can store enough B12 for many years of supply, so that daily
ingestion of B12 is not required. Most of the B12 present in animal tissues
is in one of the two coenzyme forms, adnosylcobalamin or methylcobalamin,
and not actual vitamin B12 (cobalamin), which may be present due to diffusion
from gut bacteria or active transport using intrinsic factor. Vitamin B12
is also water soluble and therefore easily lost, whereas B12 coenzymes will
remain in the liver and nerve cells, and can be effectively recycled. B12
is now obtained by deep fermentation.
According to Leonard Mervyn, B.Sc., PH.D., C.Chem F.R.S.C, in Thorsons Complete
Guide to Vitamins & Minerals, pp42, 8 µg of B12 can be absorbed at any one
time by the intrinsic factor and calcium mechanism, only 1% being absorbed
by simple diffusion following oral dose. According to Mervyn, pig's liver
contains 25.0µg/100g of B12, therefore 100g of pigs liver will result in 8.017µg
of B12 absorbed, assuming digestion is healthy.
Vitamin B12 is produced exclusively by microorganisms, but is also found in
animal flesh due to ingestion, or presence of the micro organisms in the gut.
However, since grazing "meat animals" tend to accumulate heavy metals from
the environment, it might be suggested that animal sources of B12 are not
as "good" a source as might be supposed. Poultry, especially chickens, are
routinely fed fishmeal, which may contain significant amounts of mercury and
other heavy metals. Bottom feeding rather than deep sea fish contain the most
mercury. Vegans, by avoiding eating higher on the food chain, will therefore
accumulate less heavy metals (via diet) and may require far less B12 as a
result of that risk factor. We may therefore expect to find a lower incidence
of dementia, caused by heavy metal intoxication, amongst amalgam free vegans.
B12 is a vitamin required for blood formation and rapidly growing tissues.
Methylcobalamin production requires cobalamin and is the cobalamin found in
the central nervous system (CNS) and brain where it transports methyl groups
(-CH3) to proteins in the myelin. It is for these reasons that B12 deficiency
leads to anaemia (blood disorders include macrocytos and pernicious anaemia)
and neurological disorders (Alzheimer's disease and suspected amalgam related
disorders). There are, as with many diseases, usually more than one factor
which may be involved with causation. Given that the former disorders are
rare, even in vegans who have low B12 intakes, what I am more concerned about
is the potential for neurological disorders that may be subclinical. This
occurs because it is possible to have a deficiency of B12 in the CNS even
when blood levels of B12 are "normal", or what is called non-anaemic deficiencies.
These occur for meat eaters with huge B12 intakes as well as for vegans. So
laying the blame for neurological problems on veganism or indeed any alleged
B12 intake deficiency is not always accurate, since increased B12 dietary
intake will evidently, not always work. In these serious cases B12 is usually
injected since dietary availability of B12 can be as low as 1% of the total
ingested for mega B12 doses, and some patients do not convert dietary B12
to the methylcobalamin required for normal neurological activity so well.
Symptoms could include: disturbed sense of co-ordination, paraesthesiae, loss
of memory, abnormal reflexes, weakness, loss of muscle strength, exhaustion,
confusion, low self-confidence, spacticity, incontinence, impaired vision,
abnormal gait, frequent need to pass water and psychological deviances. Non-anaemic
deficiencies play a role in diseases such as Multiple Sclerosis, Fibromyalgia,
Diabetes and Chronic Fatigue Syndrome. Schizophrenia has also been successfully
treated with B12 plus other supplements, and cardiovascular disease is linked
to B12 deficiency while herpes zoster used to be treated with B12 injections
back in the 1950s.
Just as mercury may cause B12 deficiency in the nervous system, so alcohol
can cause deficiency in tissues. Even worse, alcohol seems to raise serum
levels of vitamin B12, so that the deficiency is masked and the subject may
look like they have higher than normal B12 levels! Whether these effects correlate
to alcohol intake, or are only found in "alcoholics" is not clear.
The Recommended Daily Allowances (RDAs) are (µg/day): 0.3 at age 0-6 months,
0.5 for 6-12 months, 0.7 for 1-3 years, 1.0 for 4-6 years, 1.4 for 7-10 years,
2.0 for adolescents and adults, 2.2 in pregnancy and 2.6 in lactation. Usual
intakes are about 4-8 µg/d. Pregnant, lactating, and long-term strict vegetarians
should take supplements providing the RDA.
The stomach secretes intrinsic factor that binds B12 and mediates its absorption
at receptor sites in the ileum. Inadequate intrinsic factor secretion occurs
in pernicious anemia, an autoimmune disease. In the elderly, atrophic gastritis
is commonly associated with B-12 malabsorption and deficiency. Because the
absorbed vitamin is secreted in bile and subsequently reabsorbed, deficiency
symptoms can take 20 years to develop from low intakes, e.g., in strict vegetarians.
However, in malabsorption, deficiency occurs in months or a few years because
absorption from both the diet and enterohepatic circulation is impaired.
The application of sensitive metabolic tests, such as the deoxyuridine suppression
test and measurement of homocysteine and methylmalonic acid, to cobalamin
status has identified the entity of mild, preclinical B12 deficiency. This
state, common in the elderly, responds to cobalamin therapy. Preclinical deficiency
may exist within the nervous system as well, although this requires further
study. Nevertheless, it is well to remember that not all low B12 levels and
not all abnormal metabolite results reflect cobalamin deficiency.
Interpretation of metabolic results still requires caution, as do proposals
to raise the cut-off point for low B12 levels to capture some normal levels
that are associated with metabolic abnormality. The recognition of mild, preclinical
deficiency has opened up many important issues. These include identifying
its causes, what should be done about it, and what the clinical impact of
the hyperhomocysteinemia itself is. Although malabsorptive disorders, especially
food-cobalamin malabsorption, underlie about half of all cases of preclinical
deficiency, no cause can be found in the remainder of these cases; poor dietary
intake appears to be uncommon. In addition, unusual states of neurologically
symptomatic cobalamin deficiency are being recognized, such as nitrous oxide
exposure in patients with unrecognized deficiency and severe deficiency in
children of mildly deficient mothers. All of these have broadened and complicated
the picture of B12 deficiency while providing greater opportunities for prevention.
Vitamin B12 (cobalamin) deficiency associated neuropathy, originally called
subacute combined degeneration, is particularly common in the elderly. The
potential danger today is that with supplementation with folic acid of dietary
staples such as flour, that the incidenceof this disease could rise as folic
acid, as opposed to natural folate (N5CH3HFGlu1), enters the cell and the
metabolic cycle by a cobalamin independent pathway. This chapter briefly describes
the clinical presentation of the disease, which unless treated will induce
permanent CNS damage. The biochemical basis of the interrelationship between
folate and cobalamin is the maintenance of two functions, nucleic acid synthesis
and the methylation reactions. The latter is particularly important in the
brain and relies especially on maintaining the concentration of S-adenosylmethionine
(SAM) which, in turn, maintains the methylation reactions whose inhibition
is considered to cause cobalamin deficiency associated neuropathy. SAM mediated
methylation reactions are inhibited by its product S-adenosylhomocysteine
(SAH). This occurs when cobalamin is deficient and, as a result, methionine
synthase is inhibited causing a rise of both homocysteine and SAH. Other potential
pathogenic processes related to the toxic effects of homocysteine are direct
damage to the vascular endothelium and inhibition of N-methyl-D-aspartate
receptors.
Mild B12 deficiency is most common in elderly white men and least common in
black and Asian American women. Hyperhomocysteinemia, which is most strongly
associated with low cobalamin concentrations, is also most common in elderly
whites, whereas that associated with renal insufficiency is more common in
blacks and Asian Americans. Ethnic differences in cobalamin deficiency and
the homocysteine patterns associated with it or with renal insufficiency warrant
consideration in supplementation strategies.
-John Coleman. An Introduction To Cobalamin Metabolism-cobalamins: form, function,
inhibitors, a vegan perspective
-Carmel R. Current concepts in cobalamin deficiency. Annu Rev Med 2000;51:357-75
-Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and
folate. Br Med Bull 1999;55(3):669-82
-Ralph Carmel, Ralph Green, Et al. Serum cobalamin, homocysteine, and methylmalonic
acid concentrations in a multiethnic elderly population: ethnic and sex differences
in cobalamin and metabolite abnormalities. merican Journal of Clinical Nutrition,
Vol. 70, No. 5, 904-910, November 1999
Good Diet Plans